Background: Osteopontin (OPN) splice variants are identified as predictors of tumour progression and therapeutic resistance in certain types of solid tumours. However, their roles in gastric cancer (GC) remain poorly characterized. The current study sought to assess the prognostic value of the three OPN splice variants (namely OPN-a, OPN-b, and OPN-c) in gastric cancer and their potential functions within gastric cancer cells.

Methods: RNA extraction and reverse transcription were performed using our clinical cohort of gastric carcinomas and matched normal tissues (n = 324 matched pairs). Transcript levels were determined using real-time quantitative PCR. Three OPN splice variants overexpressed cell lines were created from the gastric cancer cell line HGC-27. Subsequently, biological functions, including cell growth, adhesion, migration, and invasion, were studied. The potential effects of OPN isoforms on cisplatin and 5-Fu were evaluated by detecting cellular reactive oxygen species (ROS) levels in the HGC-27-derived cell lines.

Results: Compared with normal tissues, the expression levels of three splice variants were all elevated in gastric cancer tissues in an order of OPN-a > OPN-b > OPN-c. The OPN-a level significantly increased with increasing TNM staging and worse clinical outcome. There appeared to be a downregulation for OPN-c in increasing lymph node status ( < 0.05), increasing TNM staging, and poor differentiation. High levels of OPN-a and OPN-b were correlated with short overall survival and disease-free survival of gastric cancer patients. However, the low expression of OPN-c was significantly associated with a poor prognosis. Functional analyses further showed that ectopic expression of OPN-c suppressed in vitro proliferation, adhesiveness, migration, and invasion properties of HGC-27 cells, while the opposite role was seen for OPN-a. Cellular ROS detection indicated that OPN-a and OPN-c significantly promoted ROS production after treatment with 5-Fu comparing to OPN-vector, while only OPN-a markedly induced ROS production after treatment with cisplatin.

Conclusion: Our results suggest that OPN splice variants have distinguished potential to predict the prognosis of gastric cancer. Three OPN variants exert distinctive functions in gastric cancer cells. Focusing on specific OPN isoforms could be a novel direction for developing diagnostic and therapeutic approaches in gastric cancer.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8305399PMC
http://dx.doi.org/10.3390/cells10071820DOI Listing

Publication Analysis

Top Keywords

gastric cancer
40
splice variants
24
opn splice
16
three opn
12
opn-a opn-b
12
gastric
11
cancer
10
opn-b opn-c
8
functions gastric
8
normal tissues
8

Similar Publications

Early cancer detection substantially improves the rate of patient survival; however, conventional screening methods are directed at single anatomical sites and focus primarily on a limited number of cancers, such as gastric, colorectal, lung, breast, and cervical cancer. Additionally, several cancers are inadequately screened, hindering early detection of 45.5% cases.

View Article and Find Full Text PDF

In recent years, the incidence of gastric cancer (GC) has been on the rise, surgical procedures usually require the removal of part of gastric tissue connected with the tumor lesion, which leads to poor postoperative health and adverse prognosis in patients. Probiotics, as an active microorganism, play an important role in improving gastrointestinal function and enhancing immunity. In this study, we randomized 135 GC patients into a control group, a probiotic group and a combination group.

View Article and Find Full Text PDF

Health utility scores of six common cancers in China measured by SF-6Dv2.

Health Qual Life Outcomes

January 2025

School of Health Management, Harbin Medical University, Harbin, 150081, China.

Purpose: Given the recent update of SF-6Dv2, detailed data on utility scores for cancer patients by cancer type remain scarce in China and other regions, which limits the precision of cost-utility analyses (CUA) in cancer interventions. The aim of the study was to systematically evaluate utility scores of six common cancers in China measured using SF-6Dv2, and identify the potential factors associated with utility scores.

Methods: A hospital-based cross-sectional survey was conducted from August 2022 to December 2023.

View Article and Find Full Text PDF
Article Synopsis
  • The study explores the effectiveness and safety of combining nivolumab, an immunotherapy drug, with chemotherapy in patients with a specific type of metastatic gastric cancer co-expressing FGFR2 and PD-L1.
  • A total of 23 patients were treated, showing a 1-year progression-free survival (PFS) rate of 30.4% and a median overall survival (OS) of 15.1 months, though the primary endpoint of improved 1-year PFS was not achieved.
  • The results highlight the need for future research on patient selection and potential combination therapies to enhance treatment outcomes in this patient population.
View Article and Find Full Text PDF

Risk assessment for esophageal cancer after bariatric surgery: a comparative cohort study between sleeve gastrectomy and gastric bypass.

Surg Obes Relat Dis

December 2024

Department of Digestive Surgery, Magellan Center, Bordeaux University Hospital Pessac, Bordeaux, France; BRIC (BoRdeaux Institute of onCology), UMR1312, INSERM, Univ. Bordeaux, Bordeaux, France. Electronic address:

Background: The risk of esophageal cancer after bariatric surgery is a matter of debate.

Objective: This study aims to evaluate the risk of esophageal cancer following sleeve gastrectomy (SG) and gastric bypass (GB).

Methods: We extracted data from the national discharge database (Programme De Médicalisation des Systèmes d'Information) for patients who underwent bariatric surgery in France between 2007 and 2020.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!